BC
TARS icon

Bridgefront Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Bridgefront Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,729
Closed -$435K – 828
2025
Q2 		$435K Buy
+10,729
New +$483K 0.12% 310

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bridgefront Capital's TARS Position: Q3 2025 in Review

Bridgefront Capital sold out of Tarsus Pharmaceuticals (TARS) in Q3 2025, closing a stake of 10,729 shares — an estimated $435K sold.

Bridgefront Capital first reported a position in TARS in Q2 2025 and held it in 1 quarter. The position peaked at $435K in Q2 2025. 220 funds tracked by Wall St. Rank hold TARS as of Q3 2025.

  • Bridgefront Capital reported no remaining Tarsus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Bridgefront Capital sold 10,729 Tarsus Pharmaceuticals shares in Q3 2025, an estimated $435K.
  • Bridgefront Capital first reported a position in Tarsus Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Bridgefront Capital's Tarsus Pharmaceuticals position peaked at $435K in Q2 2025.
  • 220 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2025.

Based on Bridgefront Capital's 13F filing for Q3 2025, filed 14 Nov 2025.